Mark Voll Biography and Net Worth

CFO of RenovoRx

Mark Voll is a seasoned financial executive with more than three decades of leadership experience in the semiconductor and high‑technology sectors. Throughout his career, he has earned a reputation as a trusted financial leader adept at guiding high‑growth companies through pivotal transitions, including IPOs, mergers, acquisitions, and large‑scale operational expansion. Mr.Voll has successfully guided companies through initial public offerings and subsequent exits, including Techwell, Inc. (IPO in 2006, acquired by Intersil in 2010), Montage Technology (IPO in 2013, acquired by PDSTI in 2014), and Aquantia Corporation (IPO in 2017, acquired by Marvell Technology in 2019). He holds a Bachelor of Science in Accounting from Providence College.

What is Mark Voll's net worth?: The estimated net worth of Mark Voll is at least $343.56 thousand as of May 19th, 2026. Voll owns 142,380 shares of RenovoRx stock worth more than $343,563 as of September 2nd. This net worth approximation does not reflect any other assets that Voll may own. Learn More about Mark Voll's net worth.
How do I contact Mark Voll?: The corporate mailing address for Voll and other RenovoRx executives is 333 W. SANTA CLARA STREET SUITE 900, SAN JOSE CA, 95110. RenovoRx can also be reached via phone at 650-284-4433 and via email at [email protected]. Learn More on Mark Voll's contact information.
Has Mark Voll been buying or selling shares of RenovoRx?: Mark Voll has not been actively trading shares of RenovoRx in the last ninety days. Most recently, on Tuesday, May 19th, Mark Voll bought 25,000 shares of RenovoRx stock. The stock was acquired at an average cost of $0.79 per share, with a total value of $19,750.00. Following the completion of the transaction, the chief financial officer now directly owns 142,380 shares of the company's stock, valued at $112,480.20. Learn More on Mark Voll's trading history.
Who are RenovoRx's active insiders?: RenovoRx's insider roster includes Laurence Marton (Director), and Mark Voll (CFO). Learn More on RenovoRx's active insiders.
Are insiders buying or selling shares of RenovoRx?: In the last year, RenovoRx insiders bought shares 9 times. They purchased a total of 94,000 shares worth more than $79,993.85. The most recent insider tranaction occured on May, 19th when CFO Mark Voll bought 25,000 shares worth more than $19,750.00. Insiders at RenovoRx own 9.4% of the company. Learn More about insider trades at RenovoRx.
Information on this page was last updated on 5/19/2026.

Mark Voll Insider Trading History at RenovoRx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/19/2026	Buy	25,000	$0.79	$19,750.00	142,380

Mark Voll Buying and Selling Activity at RenovoRx

RenovoRx Company Overview

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Today's Range

Now: $2.41

$2.14

$2.48

50 Day Range

MA: $1.10

$0.85

$2.11

2 Week Range

Now: $2.41

$0.70

$2.48

Volume

1,418,723 shs

Average Volume

381,950 shs

Market Capitalization

$108.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12